Drug pricing has been a hot issue for the past few years and was debated multiple times on the campaign trail by both Trump and Hillary. So far, there’s been little action to curb drug price increases, however, with Trump more focused on arguing with the press and other lawmakers occupied with more urgent matters. For the pharma sector, this is good news, although patients are hardly celebrating.
Still, while it may seem that, for the time being at least, drug pricing is off the political agenda, investors can’t rest easy thanks to a new report from Credit Suisse.
The report,...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
